Crucell's Q1 hit by Quinvaxem shipments
This article was originally published in Scrip
Executive Summary
Crucell's combined revenues and other operating income were €66 million for the first quarter, down by 11% on the same period last year. The decrease was attributed to the timing of shipments of Quinvaxem, its paediatric pentavalent vaccine.